Aspirin is a substrate for paraoxonase-like activity: Implications in atherosclerosis

Atherosclerosis

Volumn 191, Issue 2, 2007, Pages 272-275

  Santanam, Nalini ^a   Parthasarathy, Sampath ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Anti atherosclerosis; Antioxidant; HDL; Oxidation; Salicylic acid

Indexed keywords

4 NITROPHENYLACETIC ACID; ACETIC ACID DERIVATIVE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; NITROSALICYLIC ACID; PARAOXON; SALICYLIC ACID; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROSCLEROSIS; DRUG EFFECT; DRUG HYDROLYSIS; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; NITRATION; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL;

ADULT; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ASPIRIN; ATHEROSCLEROSIS; BINDING, COMPETITIVE; BIOTRANSFORMATION; HUMANS; HYDROLYSIS; NITROPHENOLS; PARAOXON; PLATELET AGGREGATION INHIBITORS; SALICYLIC ACID;

EID: 33947252213     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.05.027     Document Type: Article

References (36)

1. Bredie S.J., Wollersheim H., Verheugt F.W., and Thien T. Low-dose aspirin for primary prevention of cardiovascular disease. Semin Vasc Med 3 (2003) 177-184
2. van Gijn J., and Algra A. Aspirin and stroke prevention. Thromb Res 110 (2003) 349-353
3. Breddin H.K. Aspirin and platelet function. J Thromb Haemost 2 (2004) 1216-1218
4. Cyrus T., Yao Y., Tung L.X., and Pratico D. Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin. Atherosclerosis 184 (2006) 8-14
5. Rus H., and Niculescu F.I. Inflammation, aspirin, and the risk of cardiovascular disease. N Engl J Med 337 (1997) 423 (author reply 423-4)
6. Paul A., Calleja L., Camps J., et al. The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. Life Sci 68 (2000) 457-465
7. Wallace J.L., Ignarro L.J., and Fiorucci S. Potential cardioprotective actions of no-releasing aspirin. Nat Rev Drug Discov 1 (2002) 375-382
8. Verbeeck R.K., Blackburn J.L., and Loewen G.R. Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 8 (1983) 297-331
9. Scheier L. Salicylic acid: one more reason to eat your fruits and vegetables. J Am Diet Assoc 101 (2001) 1406-1408
10. La Du B. Human serum paraoxonase/arylesterase. In: Inc P.P. (Ed). Pharmacogenetics of Drug Metabolism (1992), Kalow W., New York 51-91
11. La Du B.N. Structural and functional diversity of paraoxonases. Nat Med 2 (1996) 1186-1187
12. Navab M., Hama-Levy S., Van Lenten B.J., et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 99 (1997) 2005-2019
13. Ng C.J., Shih D.M., Hama S.Y., et al. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 38 (2005) 153-163
14. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., and Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 15 (1995) 1812-1818
15. Mackness B., Davies G.K., Turkie W., et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol 21 (2001) 1451-1457
16. Chung B.H., Wilkinson T., Geer J.C., and Segrest J.P. Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J Lipid Res 21 (1980) 284-291
17. De Geest B., Stengel D., Landeloos M., et al. Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis. Arterioscler Thromb Vasc Biol 20 (2000) E68-E75
18. Navab M., Hama S.Y., Anantharamaiah G.M., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 41 (2000) 1495-1508
19. Hoak J.C. Mechanisms of action: aspirin. Thromb Res Suppl 4 (1983) 47-51
20. Kalgutkar A.S., Crews B.C., Rowlinson S.W., et al. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 280 (1998) 1268-1270
21. Xiao G., Tsai A.L., Palmer G., et al. Analysis of hydroperoxide-induced tyrosyl radicals and lipoxygenase activity in aspirin-treated human prostaglandin H synthase-2. Biochemistry 36 (1997) 1836-1845
22. Lecomte M., Laneuville O., Ji C., DeWitt D.L., and Smith W.L. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 269 (1994) 13207-13215
23. Van Der Ouderaa F.J., Buytenhek M., Nugteren D.H., and Van Dorp D.A. Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid. Eur J Biochem 109 (1980) 1-8
24. La Du B. Plasma esterase activity and the metabolism of drugs with ester groups. Ann NY Acad Sci 179 (1971) 684-694
25. White K.N., and Hope D.B. Partial purification and characterization of a microsomal carboxylesterase specific for salicylate esters from guinea-pig liver. Biochim Biophys Acta 785 (1984) 138-147
26. Blatter-Garin M.C., Kalix B., De Pree S., and James R.W. Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1. Diabetologia 46 (2003) 593-594
27. Cyrus T., Sung S., Zhao L., et al. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 106 (2002) 1282-1287
28. Maree A.O., and Fitzgerald D.J. Aspirin and coronary artery disease. Thromb Haemost 92 (2004) 1175-1181
29. Frishman W.H. Cyclooxygenase inhibition in patients with coronary artery disease. J Am Coll Cardiol 43 (2004) 532-533
30. Adams P.C., Badimon J.J., Badimon L., Chesebro J.H., and Fuster V. Role of platelets in atherogenesis: relevance to coronary arterial restenosis after angioplasty. Cardiovasc Clin 18 (1987) 49-71
31. Amann R., and Peskar B.A. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol 447 (2002) 1-9
32. Betts W.H., Whitehouse M.W., Cleland L.G., and Vernon-Roberts B. In vitro antioxidant properties of potential biotransformation products of salicylate, sulphasalazine and amidopyrine. J Free Radic Biol Med 1 (1985) 273-280
33. Drew J.E., Arthur J.R., Farquharson A.J., et al. Salicylic acid modulates oxidative stress and glutathione peroxidase activity in the rat colon. Biochem Pharmacol 70 (2005) 888-893
34. Gelvan D., Moreno V., Gassmann W., Hegenauer J., and Saltman P. Metal-ion-directed site-specificity of hydroxyl radical detection. Biochim Biophys Acta 1116 (1992) 183-191
35. Aviram M., Rosenblat M., Billecke S., et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26 (1999) 892-904
36. Karabina S.A., Lehner A.N., Frank E., Parthasarathy S., and Santanam N. Oxidative inactivation of paraoxonase-implications in diabetes mellitus and atherosclerosis. Biochim Biophys Acta 1725 (2005) 213-221